Viracta Therapeutics, Inc. - VIRX STOCK NEWS

Viracta Therapeutics, a precision oncology company focused on virus-associated malignancies, will present at key investor conferences this May. The first is the RBC Capital Markets 2022 Global Healthcare Conference on May 18, 2022, at 9:00 a.m. EDT, followed by the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:30 a.m. EDT. Both presentations will feature a fireside chat format. Investors can access live webcasts on the Viracta website, available for 30 days post-event. Viracta's lead therapy, Nana-val, is in ongoing clinical trials targeting EBV-positive malignancies.

Viracta Therapeutics (Nasdaq: VIRX) reports significant clinical and financial updates for Q1 2022. The company continues global expansion of the NAVAL-1 trial for Nana-val in EBV-positive lymphoma, with updates on advancing cohorts expected in H2 2022. Preliminary safety and efficacy data for Nana-val in advanced EBV-positive solid tumors are also anticipated later this year. As of March 31, 2022, cash and cash equivalents stand at $92.2 million, projected to fund operations into mid-2024. The Q1 net loss was approximately $10.5 million, a notable reduction from the previous year's loss.

On April 20, 2022, Viracta Therapeutics (Nasdaq: VIRX) announced a webinar scheduled for April 27 at 11:00 AM EDT. The event will focus on Nana-val, a combination therapy of nanatinostat and valganciclovir, targeting advanced Epstein-Barr virus-positive solid tumors. Key opinion leader Ezra Cohen, MD, will present the current treatment landscape for nasopharyngeal carcinoma and discuss the urgent need for new treatments. Viracta's management will also provide updates on ongoing clinical trials for Nana-val, followed by a Q&A session.

Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. EDT. The presentation will focus on the company's precision oncology initiatives targeting virus-associated malignancies, particularly its lead product candidate, Nana-val. This all-oral therapy combines nanatinostat and valganciclovir and is currently being evaluated in multiple trials for treating Epstein-Barr virus-positive lymphomas and nasopharyngeal carcinoma. A webcast of the presentation will be available on the Viracta website.

Viracta Therapeutics (Nasdaq: VIRX) announced the approval of non-qualified stock options for a new non-executive employee to purchase 200,000 shares at an exercise price of $3.04 per share, equal to the March 17, 2022 closing price. The options will vest over four years, with 25% vesting after one year and the remainder in monthly increments, contingent on continuous employment. This grant is part of Viracta's 2021 Inducement Equity Incentive Plan, designed to attract new talent consistent with Nasdaq Listing Rule 5635(c)(4).

Viracta Therapeutics (NASDAQ: VIRX) announced participation in the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, at 10:40 a.m. ET. The event will feature a fireside chat with company leadership, highlighting their focus on precision oncology targeting virus-associated malignancies. The webcast will be available on their website under 'Events and Webcasts' and archived for 30 days. Viracta's lead candidate, Nana-val, is currently in clinical trials for treating Epstein-Barr virus-positive lymphomas and other related cancers.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology firm, announced that CEO Dr. Ivor Royston will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 5:00 p.m. ET. The presentation can be accessed via webcast on the Investors section of Viracta's website, with an archive available for 60 days. Viracta focuses on virus-associated malignancies, evaluating its investigational drug nanatinostat in pivotal trials for Epstein-Barr virus-positive lymphoma and other cancers.

Viracta Therapeutics (Nasdaq: VIRX) announced the first patient dosing in the Phase 1b/2 trial of its all-oral combination therapy Nana-val (nanatinostat and valganciclovir) for patients with EBV-positive recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). This trial aims to evaluate Nana-val's safety and efficacy, both alone and in combination with pembrolizumab. The need for effective treatment options is critical as advanced NPC patients face poor outcomes. The trial includes a dose escalation phase and a dose expansion cohort for other advanced EBV+ solid tumors.

Viracta Therapeutics (Nasdaq: VIRX), a precision oncology firm, announced its upcoming presentation at the H.C. Wainwright BIOCONNECT Virtual Conference scheduled for January 10, 2022, starting at 7:00 a.m. ET. The pre-recorded webcast will be accessible on-demand at the Viracta website and will be archived for 90 days.

Viracta is focusing on virus-associated malignancies with its investigational drug, nanatinostat, currently in pivotal trials for EBV-positive lymphoma and other related cancers.